ZDHHC11 Activators encompass a variety of chemical compounds that indirectly augment the functional activity of ZDHHC11 through distinct signaling pathways and biochemical processes. Palmitoyl Coenzyme A, the substrate for ZDHHC11's palmitoylation activity, directly enhances its function, as ZDHHC11 transfers palmitoyl groups to target proteins, a crucial post-translational modification. Analogously, 2-Bromopalmitate, by inhibiting protein palmitoylation, necessitates increased ZDHHC11 activity for effective palmitoylation. The role of ZDHHC11 in lipid modification is further emphasized by compounds like Cerulenin and Fumonisin B1, which inhibit fatty acid synthase and ceramide synthase, respectively, thereby shifting cellular dependency to ZDHHC11-mediated palmitoylation for cell signaling. Manumycin A, by inhibiting farnesyltransferase, and Myriocin, by inhibiting serine palmitoyltransferase, similarly elevate ZDHHC11's role in palmitoylation as an alternative lipid modification pathway. Curcumin's modulation of lipid raft composition could affect ZDHHC11's localization and function, considering its role in modifying proteins in these microdomains.
Furthermore, compounds like Forskolin and Nicotinamide indirectly influence ZDHHC11 activity through secondary pathways. Forskolin increases cAMP levels, leading to PKA activation, which may phosphorylate substrates that regulate or interact with ZDHHC11, thus indirectly enhancing its activity. Nicotinamide, by inhibiting sirtuins, affects acylation processes, potentially increasing the functional demand on ZDHHC11-mediated palmitoylation. Additionally, Triciribine and U0126, acting as AKT and MEK inhibitors respectively, affect signaling pathways that intersect with lipid signaling processes where ZDHHC11 operates. Brefeldin A, disrupting the Golgi apparatus, potentially increases reliance on ZDHHC11 for protein palmitoylation in other cellular compartments. Collectively, these activators, through their targeted influence on lipid metabolism and cell signaling pathways, enhance the functional role of ZDHHC11, particularly in the context of protein palmitoylation and cellular signaling dynamics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels. Elevated cAMP can lead to PKA activation, which may phosphorylate substrates that interact with or regulate ZDHHC11, indirectly enhancing its functional activity. | ||||||
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $161.00 $312.00 $1210.00 | 9 | |
Cerulenin inhibits fatty acid synthase, affecting lipid metabolism. This inhibition can increase the reliance on ZDHHC11-mediated palmitoylation for cell signaling, indirectly enhancing ZDHHC11 activity. | ||||||
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $200.00 $680.00 | 18 | |
Fumonisin B1 inhibits ceramide synthase, altering sphingolipid metabolism. This disruption can modify the lipid environment where ZDHHC11 operates, potentially enhancing its palmitoylation activity. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A is a farnesyltransferase inhibitor, affecting protein prenylation. This can shift cellular dependency to palmitoylation, indirectly enhancing ZDHHC11's role in this process. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin modulates lipid raft composition and signaling, which could affect the localization and function of ZDHHC11, as ZDHHC11 is involved in modifying proteins associated with lipid rafts. | ||||||
Myriocin (ISP-1) | 35891-70-4 | sc-201397 | 10 mg | $150.00 | 8 | |
Myriocin is a potent inhibitor of serine palmitoyltransferase, impacting sphingolipid synthesis. This alteration in lipid composition could increase the functional demand on ZDHHC11-mediated palmitoylation. | ||||||
Nicotinamide | 98-92-0 | sc-208096 sc-208096A sc-208096B sc-208096C | 100 g 250 g 1 kg 5 kg | $44.00 $66.00 $204.00 $831.00 | 6 | |
Nicotinamide, as an inhibitor of sirtuins, may affect acylation processes, including palmitoylation. This could indirectly enhance the role of ZDHHC11 in maintaining protein palmitoylation levels. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine, an AKT inhibitor, affects multiple signaling pathways. By modulating AKT activity, it could influence pathways that regulate or are affected by ZDHHC11-mediated palmitoylation. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts Golgi apparatus function, which could affect protein trafficking and modification processes, potentially increasing reliance on ZDHHC11 for protein palmitoylation in other cellular compartments. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor affecting the MAPK/ERK pathway. This pathway can interact with lipid signaling pathways, potentially enhancing the demand for ZDHHC11-mediated palmitoylation in certain signaling contexts. | ||||||